| Previous close | 1.2400 |
| Open | 2.5600 |
| Bid | 0.0000 |
| Ask | 1.0000 |
| Strike | 25.00 |
| Expiry date | 2024-08-16 |
| Day's range | 1.2400 - 2.5900 |
| Contract range | N/A |
| Volume | |
| Open interest | 8 |
GuruFocus.comAlpine Immune Sciences Inc (ALPN) Reports Q1 2024 Financials Amid Pending Acquisition by Vertex ...
Financial Performance Aligns with Analyst Projections Despite Revenue Dip
Business WireAlpine Immune Sciences Reports First Quarter 2024 Financial Results
SEATTLE, May 09, 2024--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024.
Insider MonkeyVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2024 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2024 Earnings Call Transcript May 6, 2024 Vertex Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.76, expectations were $4.07. Vertex Pharmaceuticals Incorporated isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome […]
© 2024 Yahoo. All rights reserved.